CTOs on the Move

Enliven Therapeutics

www.enliventherapeutics.com

 
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Warner Chilcott

Warner Chilcott is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemBridge

ChemBridge, Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurelis

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.

STI Technologies

STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.